Nichi-Iko Pharmaceutical Co., Ltd.

topics

September 27, 2017
About Joint Promotion of Infliximab BS for I.V.Infusion 100mg "Nichi-Iko"
September 27, 2017
About Marketing Approval for Infliximab BS for I.V.Infusion 100mg "AYUMI"
September 27, 2017
About Marketing Approval for Infliximab BS for I.V.Infusion 100mg "Nichi-Iko" and the Status of Development in the U.S.A.
September 8, 2017
Consolidated Financial Results for the 1st Quarter of the Fiscal Year Ending March 31, 2018
August 9, 2017
Year Ending March 31, 2018 Results of 1st Quarter Settlement of Accounts Supplementary Material (Apr.1 to Jun.30 2017)
July 14, 2017
Licensing Agreement for Marketing Rights to Infliximab BS for I.V.Infusion 100mg "AYUMI"
June 19, 2017
Consolidated Financial Results for the Fiscal Year Ended March 31, 2017
May 30, 2017
Notice of the 53nd Ordinary General Meeting of Shareholders
May 10, 2017
Consolidated Financial Results for the Fiscal Year Ended March 31, 2017 Results Settlement of Accounts Supplementary Material (Apr.1 2016 to Mar.31 2017)
February 28, 2017
Consolidated Financial Results for the 3rd Quarter of the Fiscal Year Ending March 31, 2017
February 8, 2017
Year Ending March 31, 2017 Results of 3rd Quarter Settlement of Accounts Supplementary Material (Apr.1 to Dec.31 2016)
December 1, 2016
Consolidated Financial Results for the 2nd Quarter of the Fiscal Year Ending March 31, 2017
November 7, 2016
Year Ending March 31, 2017 Results of 2nd Quarter Settlement of Accounts Supplementary Material (Apr.1 to Sep.30 2016)
August 31, 2016
Consolidated Financial Results for the 1st Quarter of the Fiscal Year Ending March 31, 2017
August 08, 2016
Year Ending March 31, 2017 Results of 1st Quarter Settlement of Accounts Supplementary Material (Apr.1 to Jun.30 2016)
June 13, 2016
Consolidated Financial Results for the Fiscal Year Ended March 31, 2016
May 31, 2016
Notice of the 52nd Ordinary General Meeting of Shareholders
December 2, 2015
Notice of Sale of Shares Held by Nichi-Iko Pharmaceutical Co., Ltd.,Termination of Capital Alliance and Continuation of Business Alliance
November 5, 2014
Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31,2015
August 11, 2014
Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31,2015
June 20, 2014
Notice Concerning Issuance of Long-term Stock Options for Stock-based Compensation
June 20, 2014
New Products Released in June 2014
May 13, 2014
Scheduled Dividends for the Fiscal Year Ending March 31, 2015
May 12, 2014
Revision of the 6th Mid-term Business Plan "Pyramid"
May 12, 2014
Year Ended March 31, 2014 Results of Full year Settlement of accounts supplementary material (Apr.1 2013 to Mar.31 2014)
May 12, 2014
Consolidated Financial Results for the Fiscal Year Ended March 31, 2014
March 10, 2014
Notice of Decision on Name of New Company for Business Succession of Fuji Plant between the Company and Astellas Pharma Group: Nichi-Iko Pharma Tech Co., Ltd.
February 12, 2014
Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2014
February 12, 2014
Notice of Establishment of Subsidiary in USA
January 30, 2014
Notice Concerning the Transfer of Nichi-Iko Pharmaceutical Co., Ltd. Stock Acquisition Rights No.5
January 28, 2014
Notice Concerning the Status of Exercise (Final Status of Exercise by General Investors) and the Acquisition of Nichi-Iko Pharmaceutical Co., Ltd. Stock Acquisition Rights No.5
January 24, 2014
Notice Concerning the Status of Exercise of Nichi-Iko Pharmaceutical Co., Ltd. Stock Acquisition Rights No.5 (As of January 22, 2014) and the Total Number of Issued Shares (As of January 23, 2014)
January 24, 2014
Notice of Establishment of Local Corporation in Thailand
January 22, 2014
Notice Concerning the Status of Exercise of Nichi-Iko Pharmaceutical Co., Ltd. Stock Acquisition Rights No.5 (As of January 20, 2014) and the Total Number of Issued Shares (As of January 21, 2014)
January 20, 2014
Notice Concerning the Status of Exercise of Nichi-Iko Pharmaceutical Co., Ltd. Stock Acquisition Rights No.5 (As of January 16, 2014) and the Total Number of Issued Shares (As of January 17, 2014)
January 16, 2014
Notice Concerning the Status of Exercise of Nichi-Iko Pharmaceutical Co., Ltd. Stock Acquisition Rights No.5 (As of January 14, 2014) and the Total Number of Issued Shares (As of January 15, 2014)
January 16, 2014
Notice Concerning Transfer of Major Shareholder
January 14, 2014
Notice Concerning the Status of Exercise of Nichi-Iko Pharmaceutical Co.,Ltd. Stock Acquisition Rights No.5 by Existing Shareholders, etc.
December 13, 2013
Notice of Final Agreement between the Company and Astellas Pharma Group for Business Acquisition of Fuji Plant
December 3, 2013
Notice Concerning Adjustment of Exercise Price of Existing Stock Option (Stock Acquisition Rights) of Nichi-Iko Pharmaceutical Co., Ltd.
December 2, 2013
Notice Concerning the Listing Date of Stock Acquisition Rights No.5 of Nichi-Iko Pharmaceutical Co., Ltd. Issued Through a Commitment-type Rights Offering
November 27, 2013
Notice Concerning the Commitment-type Rights Offering (Allotment of Listing-type Stock Acquisition Rights without Contribution) PDF Stock Acquisition Rights Exercise/Cancellation Request Form 114 KB
November 27, 2013
Explanation Concerning the Commitment-type Rights Offering (Allotment of Listing-type Stock Acquisition Rights without Contribution) (Q&A)
November 27, 2013
Notice Concerning Revision to Year-end Dividend Forecast
November 27, 2013
Investor Letter
November 27, 2013
Terms and Conditions of Allotment of the Stock Acquisition Rights No.5
November 6, 2013
Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31,2014
October 2, 2013
Statement of Agreement for Capital Alliance with Binex in Korea
September 30, 2013
Notice Concerning Determination of Terms of Issuance of Stock Options (Stock Acquisition Rights)
September 27, 2013
Notice of Basic Agreement for Business Acquisition of Fuji Plant of Astellas Pharma Group
September 9, 2013
Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)
September 9, 2013
Business Alliance with Biolab in Thailand
August 9, 2013
Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31,2014
July 19, 2013
Notice Concerning Determination of Terms of Issuance of Long-term Stock Options for Stock-based Compensation
June 21, 2013
Notice of the Resolutions at the 49th Annual General Meeting of Shareholders
June 21, 2013
Notice Concerning Issuance of Long-term Stock Options for Stock-based Compensation
June 3, 2013
Notice Concerning Issuance of Short-term and Mid-term Stock Options for Stock-based Compensation
May 14, 2013
Policy of Countermeasures against Large-Scale Acquisitions of Share Certificates, etc. of Nichi-Iko Pharmaceutical Co.,Ltd.(Takeover Defense Measures)
May 14, 2013
Notice Concerning Stock Options (Stock Acquisition Rights)
May 14, 2013
Notice Concerning Issuance of Short-term and Mid-term Stock Options for Stock-based Compensation
May 14, 2013
Consolidated Financial Results for the Fiscal Year Ended March 31,2013
March 22, 2013
Merger and Acquisition of Yakuhan Pharmaceutical Co., Ltd.
March 1, 2013
Completion of the Pyramid Building
February 12, 2013
Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2013
February 12, 2013
Establishment of Representative Office in Bangkok, Thailand
December 12, 2012
Nichi-Iko Ladies Open Golf Tournament
November 13, 2012
Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2013
August 9, 2012
Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2013
November 24, 2011
Listing on the First Section of the Tokyo Stock Exchange
October 28, 2011
Completion of Honeycomb Building, the Global Development and Quality Control Center
October 21, 2010
Capital and Business Alliance on R&D for Biosimilars
July 28, 2010
Agreement on Exclusive Representation with DKSH Group (Thailand, Malaysia, Hong Kong)
May 28, 2010
Agreement on a Strategic Partnership with Sanofi-Aventis(currently SANOFI) for Generic Pharmaceuticals in Japan

Back to Top